Netherlands· NL-35e6c5598add

Amifampridine Amarox 10 mg tabletten

A amifampridine product containing amifampridinefosfaat, registered in Netherlands by Amarox Pharma B.V.. The same ATC class is registered in 16 of our 19 countries.

ATC N07XX05

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about amifampridinefosfaatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Amifampridine is registered in 16 of 19 countries.

Countries holding a registration under ATC N07XX05 (amifampridine), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search amifampridine products by name

Amifampridine · ATC N07XX05

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of amifampridine costs, country by country.

Normalised to the WHO defined daily dose (40 mg), the median price runs from $75.59 in Switzerland to $3657.38 in France — a ×48 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Amifampridine · price per daily dose (40 mg)

USD · FX 28 Sept 2026

FR France$3657.38
CH Switzerland$75.59

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: AMIFAMPRIDINEFOSFAAT
Manufacturer: Amarox Pharma B.V.
Country: Netherlands (NL)
ATC code: N07XX05
ATC class: Amifampridine
Defined daily dose: 40 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
132982

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

82 interactions on record for amifampridine.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check amifampridine against other medicines How interaction checks work

Amifampridine · interactions on record

82 records

4 severe
78 moderate

Most severe, free to view

BupropionN06AX12severe
BupropionN07BA02severe
IohexolV08AB02severe
IopamidolV08AB04severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Amifampridine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All amifampridine products

Authorised across Europe · EMA

The same active substance is authorised in 10 EEA countries. Names it is sold under:

Germany · Amifampridin Accord, Amifampridin Amarox
France · Amifampridine Amarox, Amifampridine Biogaran
Hungary · Amifampridine Accord
Iceland · Amifampridine Serb, Firdapse
Italy · Amifampridina Accord
Liechtenstein · Amifampridine Serb, Firdapse
Norway · Amifampridin Medical Valley, Amifampridine Accord
Poland · Amifampridine Medical Valley
Portugal · Amifampridina Accord, Amifampridina Generis
Slovenia · Amifampridin Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/ea179357-dfe0-489c-841b-a6d51ac00b43
GET /v1/drugs/ea179357-dfe0-489c-841b-a6d51ac00b43?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h132982_smpc.pdf",
  "strength": null,
  "atc_label": "Amifampridine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg132982",
  "excipients": [
    "CALCIUMSTEARAAT (E 470A)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "SILICIUMDIOXIDE (E 551)"
  ],
  "substances": [
    "AMIFAMPRIDINEFOSFAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h132982.pdf",
  "authorised_at": "2025/08/28",
  "procedure_number": "NL/H/6020/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "132982",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about amifampridine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console